Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 3/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 3/20 | 0.33 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615620 | 0.91 | MCOLN2 (0.34) | SLC40A1GLO1BRD4KMT2A | |
| SCHEMBL2138380 | 0.88 | SLC40A1 (0.40) | SLC40A1GLO1CKS1BSKP2BRD4 | |
| SCHEMBL2133536 | 0.85 | KMT2A (0.46) | SLC40A1GLO1CKS1BSKP2KMT2A | |
| SCHEMBL2136575 | 0.85 | SLC40A1 (0.39) | SLC40A1GLO1CKS1BSKP2BRAF | |
| SCHEMBL2138836 | 0.85 | TBXA2R (0.41) | SLC40A1GLO1CKS1BSKP2JAK2 | |
| SCHEMBL2615604 | 0.84 | TRPV1 (0.32) | JAK2 | |
| SCHEMBL2615613 | 0.84 | SLC40A1 (0.39) | SLC40A1GLO1CKS1BSKP2KEAP1 | |
| SCHEMBL16239546 | 0.83 | USP2 (0.40) | SLC40A1GLO1CKS1BSKP2KEAP1 | |
| SCHEMBL2615621 | 0.82 | — | — | |
| SCHEMBL2140482 | 0.81 | HIF1A (0.41) | SLC40A1GLO1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | PRKAG1, PRKAB1, PRKAG2 | SLC40A1 3031/4885GLO1 1252/4885CKS1B 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.